Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of 'one linked airway disease'

Annals of Allergy, Asthma and Immunology

Volumn 84, Issue 2, 2000, Pages 176-182

  Meltzer, Eli O ^a  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MONTELUKAST; ZAFIRLUKAST;

ALLERGIC RHINITIS; ASTHMA; DRUG EFFICACY; DRUG MECHANISM; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY;

EID: 0034102104     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62750-0     Document Type: Review

References (81)

1. Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991;46:895-901.
2. Meltzer EO. The prevalence and medical and economic impact of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:S805-S828.
3. Wright AL, Holberg CJ, Martinez FD, et al. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 1994;94:895-901.
4. Baraniuk JN, Meltzer EO, Spector SL. Chronic airway diseases: reassessing the role of allergy. J Respir Dis 1996; 17:S1-S52.
5. Sibbald B, Strachan DP. Epidemiology of rhinitis. In: Busse WW, Holgate ST, eds. Asthma and rhinitis. Boston: Blackwell Scientific Publications; 1995:32-43.
6. Pedersen PA, Weeke ER. Asthma and allergic rhinitis in the same patients. Allergy 1983;38:25-29.
7. Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994;15:21-25.
8. Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal allergic rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1995;95:923-932.
9. Welsh PW, Stricker WE, Chu C-P, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987;62: 125-134.
10. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100:781-788.
11. Ronberg E, lezzoni D, Manning B, Corren J. Treatment of allergic rhinitis is associated with lower rates of asthma-related emergency room visits and hospitalizations (Abstract 980). J Allergy Clin Immunol 1998;101:5236.
12. Corren J. The impact of allergic rhinitis in bronchial asthma. J Allergy Clin Immunol 1998;101:S352-S356.
13. Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997; 99:5763-8772.
14. Drazen JM. Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Am J Respir Crit Care Med 1998;157:S233-S237.
15. Wenzel SE. New approaches to anti-inflammatory therapy for asthma. Am J Med 1998;104:287-300.
16. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996; 98:1-13.
17. Naclerio RM. Allergic rhinitis. N Engl J Med 1991;325:860-869.
18. Knani J, Campbell A, Enander I, et al. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J Allergy Clin Immunol 1992;90:880-889.
19. Schneider LC, Lester MR. Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Curr Opin Pediatr 1997;9:537-547.
20. Skoner DP, Doyle WJ, Boehm S, et al. Late phase eustachian tube and nasal allergic responses associated with inflammatory mediator elaboration. Am J Rhinol 1988;2:155-161.
21. Iliopoulos O, Proud D, Adkinson NF Jr, et al. Relationship between the early, late, and rechallenge reaction to nasal challenge with antigen: observations on the role of inflammatory mediators and cells. J Allergy Clin Immunol 1990;86:851-861.
22. Booij-Noord H, de Vries K, Sluiter HJ, Orie NGM. Late bronchial obstructive reaction to experimental inhalation of house dust extract. Clin Allergy 1972; 2:43-61.
23. Sehmi R, Wood LJ, Watson R, et al. Allergen-induced increases in IL-5 receptor α-subunit expression on how bone-marrow derived CD-34+ cells from asthmatic subjects: a novel marker of progenitor cell commitment towards eosinophilic differentiation. J Clin Invest 1997;100:2466-2475.
24. Robinson DS, Damia R, Zeibecoglou K, et al. CD34+/interleukin-5Rd messenger RNA+ cells in the bronchial mucosa in asthma: potential airway eosinophil progenitors. Am J Respir Cell Mol Biol 1999;20:9-13.
25. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323:645-655.
26. Horwitz RJ, McGill KA, Busse WW. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998;157:1363-1371.
27. Pipkorn U, Proud D, Lichtenstein LM, et al. Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J Clin Invest 1987;80:957-961.
28. Skoner DP, Lee L, Doyle WJ, et al. Nasal physiology and inflammatory mediators during natural pollen exposure. Ann Allergy Asthma Immunol 1990(65):206-210.
29. Henderson WR. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-697.
30. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-990.
31. 4 in humans. Am Rev Respir Dis 1985;131:368-372.
32. 4, and histamine in normal human subjects. Thorax 1984;39:500-504.
33. 4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clinical Allergy 1986;16:289-297.
34. Meltzer EO. The pharmacologic basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy 1997; 52(Suppl 36):33-40.
35. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: parameter documents of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:463-518.
36. Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report II. Bethesda, MD: National Institutes of Health; July 1997. Publication 98-4051.
37. Corren J, Adinoff AD, Buchmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992;90:250-256.
38. Wang D, Smitz J, De Waele M, Clement P. Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season. Int Arch Allergy Immunol 1997;114:185-192.
39. Barnes PJ. Should anti-inflammatory agents be used earlier in asthma? J Respir Dis 1998;19:S28-S34.
40. O'Shaughnessy KM, Wellings R, Gillies R, et al. Differential effects of fluticasone propionate on allergenevoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis 1993;147: 1472-1476.
41. Dworski R, Fitzgerald GA, Oates JA, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-959.
42. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331: 700-705.
43. Van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al, and the Dutch Chronic Non-Specific Lung Disease Study Group. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992;146: 547-554.
44. Waalkens HJ, Van Essen-Zandvliet EE, Hughes MD, et al. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993;148:1252-1257.
45. Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997;156: 737-743.
46. Meltzer EO, Jalowayski AA, Orgel HA, Harris AG. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J Allergy Clin Immunol 1998; 102:39-49.
47. Crowley S, Trivedi P, Risteli L, et al. Collagen metabolism and growth in prepubertal children with asthma treated with inhaled steroids. J Pediatr 1998;132:409-413.
48. Boot AM, de Jongste JC, Verberne AAPH, et al. Bone mineral density and bone metabolism of prepubertal children with asthma after long-term treatment with inhaled corticosteroids. Pediatr Pulmonol 1997;24:379-384.
49. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337:8-14.
50. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996;51: 262-266.
51. Nightingale CH. Pharmacokinetics and pharmacodynamics of fluticasone propionate: possible HPA-axis suppression during asthma treatment. Adv Ther 1998;15:129-136.
52. Garbe E, LeLorier J, Boivin J-F, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277:722-727.
53. O'Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997;127: 472-480.
54. 4 receptor antagonist. Can J Physiol Pharmacol 1995;73: 191-201.
55. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinylleukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337:690-694.
56. Leff JA, Pizzichini E, Efthimiadis A, et al. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomized placebo-controlled trial (Abstract). Am J Respir Crit Care Med 1997;155:A977.
57. Muñoz NM, Douglas I, Mayer D, et al. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am J Respir Crit Care Med 1997;155:1398-1403.
58. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 1998;158:1213-1220.
59. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6-to 14-year-old children: a randomized, double-blind trial. JAMA 1998;279: 1181-1186.
60. Calhoun WJ, Lavins BJ, Minkwitz MC, et al. Effect of zafirlukast (Accolate) on cellular mediators of inflammation. Am J Respir Crit Care Med 1998;157:1381-1389.
61. Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma; a randomized, controlled trial. Eur Respir J 1999;14:12-18.
62. 1 receptor antagonist, decreases peripheral blood eosinophils and improves signs and symptoms of asthma over a 3 month period (Abstract). J Allergy Clin Immunol 1997;99:S268.
63. 4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995;151:1734-1739.
64. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-623.
65. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204,219 (Accolate™) or cromolyn sodium (Intal®) in patients with mild to moderate asthma (Abstract 990). J Allergy Clin Immunol 1995;95:388.
66. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204,219, a potent D4 receptor antagonist. Am Rev Respir Dis 1992;145:746-749.
67. Nayak AS, Anderson PJ, Carous KL, et al. Addition of zafirlukast compared with a doubled-dosage of inhaled corticosteroids in asthmatic patients with symptoms on inhaled corticosteroids (Abstract). Eur Respir J 1998;12(Suppl 28):P2388.
68. 4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1997;61: 83-92.
69. Knorr B, Nguyen H, Villaran C, et al. Selection of a montelukast dose in 2-to 5-year-olds by a comparison of pediatric and adult single-dose pharmacokinetic (PK) profiles (Abstract). Clin Pharmacol Ther 1998;63:191A.
70. Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J 1998;11: 1232-1239.
71. Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997;126:177-183.
72. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339: 147-152.
73. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993;147: 1413-1418.
74. Meltzer SS, Hasday JD, Cohn J, et al. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996;153:931-935.
75. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998;133:424-428.
76. Ostrom N, Bronsky E, Pearlman D, et al. Effects of the leukotriene-receptor antagonist zafirlukast on exercise-induced asthma in pediatric subjects (Abstract). Eur Respir J 1997;10(Suppl 25):276s.
77. Holland S, Gertz B, Desmet M, et al. Montelukast (MON) has no effect on terfenadine (T) pharmacokinetics (PK) or QTc (Abstract). Clin Pharmacol Ther 1998;63:232A.
78. Malmstrom K, Meltzer EO, Prenner B, et al. Effects of montelukast (a leukotriene receptor antagonist), loratadine, montelukast + loratadine and placebo in seasonal allergic rhinitis and conjunctivitis (Abstract). J Allergy Clin Immunol 1998;101:S97.
79. Van Hecken A, Depré M, Verbesselt R, et al. Lack of pharmacokinetic and pharmodynamic interaction between montelukast and warfarin in healthy volunteers. J Clin Pharmacol 1999;39: 495-500.
80. Kelloway JS. Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma. Ann Pharmacother 1997;31:1012-1021.
81. Roquet A, Dahlén B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997;155:1856-1863.